Colleen Planchon
Acute Care · Providence, RINPI 1497183446
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.2% of the total across 128 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,268, 2.8 times the $449 reported in 2021. Among acute care clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 128 payments — averaging $37.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$979
- Johnson & Johnson$597
- Boehringer Ingelheim$586
- Actelion Pharmaceuticals US, Inc.$490
- AstraZeneca$386
- Amgen$371
- plus $1K from 18 others
What the payments were for
- Consulting fees$2004%
- Food & beverage$4,58394%
- Education$802%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 14 | $979 |
| Johnson & Johnson | 17 | $597 |
| Boehringer Ingelheim | 13 | $586 |
| Actelion Pharmaceuticals US, Inc. | 8 | $490 |
| AstraZeneca | 14 | $386 |
| Amgen | 11 | $371 |
| Novartis | 11 | $237 |
| Bridgebio Pharma, Inc. | 4 | $230 |
| Novo Nordisk | 4 | $198 |
| Atricure, Inc. | 1 | $121 |
| Alnylam Pharmaceuticals Inc. | 4 | $93 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $90 |
| Pfizer | 3 | $65 |
| Merck | 3 | $64 |
| Scpharmaceuticals Inc. | 3 | $59 |
| Lexicon Pharmaceuticals, Inc. | 2 | $53 |
| E.r. Squibb & Sons, L.L.C. | 2 | $43 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $43 |
| Impulse Dynamics (USA) Inc. | 2 | $42 |
| Baxter Healthcare | 1 | $38 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Bardy Diagnostics, Inc. | 1 | $14 |
| Medtronic | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$626
- UPTRAVI$262
- OPSUMIT$262
- JARDIANCE$247
- Attruby$145
- Repatha$136
- XARELTO$124
- WAINUA$123
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$121
- Wegovy$115
How this compares
$4,863 in reported general payments places this provider in the 95th percentile of 66 acute care providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,230 | $1,219,282 |
| XareltoRivaroxaban | 266 | $269,896 |
| EntrestoSacubitril/Valsartan | 231 | $248,509 |
| JardianceEmpagliflozin | 99 | $103,880 |
| Repatha SureclickEvolocumab | 93 | $83,130 |
| FarxigaDapagliflozin Propanediol | 82 | $76,143 |
| BrilintaTicagrelor | 39 | $28,810 |
| Praluent PenAlirocumab | 22 | $24,483 |
| Metoprolol Succinate | 1,432 | $21,383 |
| Repatha SyringeEvolocumab | 22 | $16,994 |
| Rosuvastatin Calcium | 682 | $9,683 |
| Atorvastatin Calcium | 778 | $9,501 |
| MultaqDronedarone Hcl | 11 | $8,351 |
| Olmesartan Medoxomil | 199 | $5,428 |
| Amlodipine Besylate | 624 | $5,072 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $65 | $1,219,2821,230 claims |
| Johnson & JohnsonXarelto | $597 | $269,896266 claims |
| NovartisEntresto | $237 | $248,509231 claims |
| Boehringer IngelheimJardiance, Pradaxa | $586 | $108,800115 claims |
| AstraZenecaFarxiga, Brilinta | $386 | $104,953121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 66 acute care providers in Rhode Island.
Other acute care in Providence
- Renee BernardProvidence$21K
- Dale SumilangProvidence$10K
- Nicole CampbellProvidence$5K
- David GardnerProvidence$5K
- Kathryn ArnerProvidence$2K
- Meghan CaridesProvidence$2K
- Holli BrousseauProvidence$2K
- Cheryl PappasProvidence$2K
- Stephanie BrownProvidence$953
- Erika LeonardProvidence$892
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.